Armata Pharmaceuticals, Inc. (ARMP)
Stock Price:
$3.17 USD
0.03 (0.96%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
59.29M |
| Revenue (ttm) |
319,000 |
| Net Income (ttm) |
-20.14M |
| Shares Out |
18.70M |
| EPS (ttm) |
-1.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$3.17 |
| Previous Close |
$3.14 |
| Change ($) |
0.03 |
| Change (%) |
0.96% |
| Day's Open |
3.20 |
| Day's Range |
3.12 - 3.20 |
| Day's Volume |
13,644 |
| 52-Week Range |
2.52 - 6.92 |
More Stats
| Market Cap |
59.29M |
| Enterprise Value |
55.24M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.70M |
| Float |
n/a |
| EPS (basic) |
-1.50 |
| EPS (diluted) |
-1.42 |
| FCF / Share |
-0.82 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
39,690 |
| Short Ratio |
2.82 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
185.85 |
| PB Ratio |
2.39 |
| Revenue |
319,000 |
| Operating Income |
-19.51M |
| Net Income |
-20.14M |
| Free Cash Flow |
-15.08M |
| Net Cash |
4.05M |
| Net Cash / Share |
0.22 |
| Gross Margin |
100.00% |
| Operating Margin |
-6,115.99% |
| Profit Margin |
-6,314.40% |
| FCF Margin |
-4,728.21% |
| ROA |
-31.42% |
| ROE |
-94.23% |
| ROIC |
-87.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.25*
(128.71% upside)
Low
5.00
Current: $3.17
High
9.00
Target: 7.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2008 |
|---|
| Revenue | - | - | 0.12 | 0.26 | 0.48 | 0.41 | 0.08 | 0.66 | 0.12 | 8.72 |
| Revenue Growth | - | - | -55.77% | -45.26% | 16.14% | 404.94% | -87.8% | 453.33% | -98.62% | - |
| Gross Profit | - | - | 0.12 | 0.26 | 0.48 | 0.41 | 0.08 | 0.66 | 0.12 | 8.72 |
| Operating Income | -19.75 | -17.66 | -16.16 | -23.38 | -10.23 | -14.11 | -12.38 | -4.02 | -3.91 | -21.17 |
| Net Income | -19.48 | -16.70 | -12.84 | -18.84 | -0.52 | 23.11 | -64.58 | -1.11 | -3.79 | -20.72 |
| Shares Outstanding | 7.83 | 4.65 | 0.46 | 0.07 | 0.04 | 0.03 | 0.01 | 0.01 | 0.01 | - |
| Earnings Per Share | -2.55 | -3.59 | -30.52 | -345.37 | -278.59 | -326.19 | -4,479.91 | -140.00 | -559.99 | -7,279.85 |
| Operating Cash Flow | -15.58 | -10.63 | -9.19 | -10.61 | -9.78 | -12.57 | -6.29 | -4.28 | - | -10.31 |
| Capital Expenditures | -0.13 | -0.81 | -0.06 | -0.28 | -0.21 | -1.20 | -0.10 | -0.05 | - | -0.66 |
| Free Cash Flow | -15.71 | -11.44 | -9.25 | -10.89 | -9.99 | -13.77 | -6.39 | -4.33 | - | -10.97 |
| Cash & Equivalents | 6.73 | 10.46 | 5.13 | 5.71 | 9.37 | 6.58 | 20.36 | 0.86 | 1.10 | 5.22 |
| Total Debt | 2.86 | - | - | 0.80 | - | - | - | 3.65 | 2.70 | - |
| Net Cash / Debt | 3.87 | 10.46 | 5.13 | 4.91 | 9.37 | 6.58 | 20.36 | -2.79 | -1.60 | 5.22 |
| Assets | 25.45 | 14.55 | 11.14 | 18.15 | 31.49 | 28.62 | 41.21 | 22.07 | 11.48 | 7.15 |
| Liabilities | 10.86 | 6.85 | 3.41 | 8.43 | 6.89 | 23.19 | 63.13 | 9.13 | 4.33 | 10.92 |
| Book Value | 14.59 | 7.69 | 7.73 | 9.72 | 12.71 | 3.44 | -22.63 | 12.94 | 7.15 | -3.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Armata Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
33 |
| CEO |
Todd R. Patrick |
Stock Information
| Ticker Symbol |
ARMP |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: ARMP |
Description
Armata Pharmaceuticals, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.